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means differed predictably and significantly across known groups based on the PASI 
and IGA. Responsiveness effect size estimates were moderate to large (0.6 to 1.4). 
CDF plots show that the percentage of responders was consistently higher in the 
treatment arms than placebo across the range of change scores. ConClusions: 
Results support the reliability, validity, and responsiveness of the PsD and its use as 
a tool to enhance treatment decisions in patients with moderate-to-severe plaque 
psoriasis.
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objeCtives: To test the reliability of the Patient Reported Scar Evaluation 
Questionnaire (PR-SEQ) in a general scar population at two time points and in two for-
mats (pen/paper and electronic). Methods: The PR-SEQ, a 30-item 4-domain meas-
ure of scar experience, was administered to a total of 512 clinic- and self-recruited 
subjects with qualifying scars. The 101 clinic-recruited subjects were administered 
the PR-SEQ in a pen/paper format at Baseline and at Timepoint 1 (T1) and Timepoint 
2 (T2) about 7 +/- 2 days apart using a computer-based version on the internet. The 
413 self-recruited subjects were administered only the internet version at T1 and T2. 
Internal consistency reliability was assessed using Cronbach’s alpha for the total T1 
cohort (n= 512); test-retest reliability was assessed using the intraclass correlation 
coefficient (ICC) based on an ANOVA model for the T1-T2 retest cohort (n= 359); and 
between forms reliability was assessed using the ICC for the clinic cohort data from 
baseline and T1 (n= 100). Results: Cronbach’s alpha was 0.96 for the PR-SEQ total 
score and 0.86 for Appearance (5 items), 0.68 for Symptoms (3 items), 0.92 for Bother (8 
items), and 0.95 for Impact (14 items) domains. The ICC for the test-retest cohort was 
0.85 for the total score and 0.76, 0.78, 0.80, and 0.81 for the domains of Appearance, 
Symptoms, Bother, and Impact, respectively. Between forms reliability was similarly 
acceptable with scores of 0.84, 0.90, 0.92, and 0.95 for the domains, and 0.94 for the 
total score. ConClusions: Overall, the two versions of the PR-SEQ demonstrated 
acceptable levels of reliability across the domains and total score, with the possible 
exception of the internal consistency of the 3-item Symptom domain. Further item 
reduction may be possible without significant risk to the reliability of the instrument.
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objeCtives: There is a paucity of evidence regarding a well-defined, reliable, and 
feasible method for measuring efficacy outcomes in acute bacterial skin and skin 
structure infection (ABSSSI) trials. Evidence suggests a relationship between a 
decrease in lesion size and patient-centered outcomes related to pain; however, 
there is no patient reported outcome (PRO) to capture additional symptoms which 
patients may experience. The goal of this study was to explore concepts of skin 
infection as reported by patients, and comprehensively capture these symp-
toms. Methods: One-on-one telephone interviews were conducted with patients 
diagnosed with an ABSSSI within the past 4-7 days in the United States. ABSSSI 
patients with a wound infection, cellulitis (including erysipelas), or major abscess 
were included. Patients were asked to describe their skin infection and how it may 
have affected their life. The data was continually analyzed using an iterative pro-
cess to identify themes and concepts which were recorded in a saturation grid. 
Saturation was monitored according to the FDA PRO guidance. Results: Thirty-
four patients participated in concept elicitation interviews from four sites. Thirteen 
patients were diagnosed with major abscess, twelve with wound infection, and 
nine with cellulitis. Mean age of the sample was 39 years (SD = 12.2); 35% were 
female. The main themes to emerge included signs (e.g., growth, color), symptoms 
(e.g., soreness), and impacts on functionality (e.g., social, physical) related to the 
skin infection. The most commonly reported symptoms included experiencing 
pain (n= 32), swelling (n= 31), and drainage or leakage at the site of the infection 
(n= 27). ConClusions: Qualitative data gathered in the initial concept elicitation 
interviews will be combined with input from experts to form the basis of a new PRO 
instrument to assess patient-reported ABSSSI symptoms. This study will also ensure 
that the newly developed PRO instrument has established qualitative content valid-
ity for the types of ABSSSI patients being interviewed.
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objeCtives: Patients identified pain as one of the key symptoms they experience 
during early development of the Psoriasis Symptom Inventory (PSI), an 8-item meas-
ure of psoriasis symptom severity. This analysis addresses the consistency and 
relevance of pain evaluated in a supplemental qualitative study in patients with 
psoriasis. Methods: Individual concept elicitation (CE) interviews and cognitive 
interviews (CI) were conducted in adults with moderate to severe plaque psoria-
sis (Body Surface Area ≥ 10, PASI ≥ 12, Physician Global Assessment ≥ 3). Subjects 
were recruited from four different US sites. Interviews were audio-recorded and 
transcribed. Concepts were identified and coded using Atlas.ti software. Additional 
questions during the interview asked patients to rate the severity of their symptoms 
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objeCtives: This study aims to review whether there is a match between how pso-
riasis patients perceive their quality of life and how this is perceived by their treating 
physicians. Methods: A cross-sectional survey of Rheumatologists/Dermatologists 
(n = 114) and their psoriasis patients (n = 689) living in the United States, conducted 
June/September 2013. Each specialist completed a comprehensive record form on 
patients consulting for their psoriasis. Patients were invited to complete a question-
naire and also the EQ-5D-5L instrument. Physicians completed the same instrument 
for how they envision the status of that same patient. Patients were split into 3 equal 
groups based on their health utility scores. Results: No significant correlation was 
found between the patient- and physician-reported health utility scores (Pearson 
correlation index = - 0,071, p = 0.396). In 34% of the cases there was a significant (> 1x 
standard deviation) mismatch between the physician and the patients’ point of view. 
Out of that 34%, 20% was an overestimation (physicians scored the patients worse 
than the patients scored themselves) and 14 % was an underestimation (patients 
scored themselves worse than the physicians scored them). In 15% of the cases 
there was a perfect match (patients and physicians generated the same health 
utility score). Mismatching was most frequent in the group with the lowest health 
utility scores. ConClusions: There is no significant relationship between health 
utility scores generated by physicians and patients. Although the evaluated patient 
is the same, there appears to be a mismatch in perception of patient wellbeing.
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objeCtives: The aims of this review were 1) to estimate the disutility of patients 
suffering from psoriasis vulgaris, using the mean EQ5D index scores and 2) to com-
pare this to patients suffering from cancer (prostate, breast, Hodgkin/non-Hodgkin 
lymphoma, the digestive system) and cardiovascular diseases (angina and heart 
failure). Methods: A systematic literature search was conducted in December 2013 
in EMBASE, MEDLINE and CENTRAL using search terms EQ5D OR EQ OR EUROQoL 
AND Psoriasis AND/OR Vulgaris. The following inclusion criteria were used: original 
research, full length papers available, mild, moderate and severe psoriasis vulgaris, 
EQ5D, English written. Four independent reviewers reviewed the titles, abstracts 
and full length papers. The full length papers meeting the inclusion criteria were 
analyzed in a data extraction table. A separate search was conducted to identify 
already published systematic literature reviews in psoriasis or any other disease 
reporting on utility based on EQ5D. The results were qualitatively compared to those 
reviews. Results: In the first search, 133 titles were identified, however after 3 
rounds of reviews (excluding 65 Titles, 44 Abstracts, 7 Full length papers) 17 papers 
were found to meet the inclusion criteria. For patients suffering from psoriasis 
vulgaris the mean EQ5D-index scores ranged from 0.52 (standard deviation 0.39) 
to 0.90 (standard deviation 0.10) for all disease severities. The second search iden-
tified two systematic literature reviews one in cancer and one in cardiovascular 
diseases investigating utility based on EQ5D. Corresponding ranges for cancer and 
cardiovascular diseases are 0.33 (standard deviation 0.4) to 0.93 (standard deviation 
0.12) and 0.24 (standard deviation 0.39) to 0.90 (standard deviation 0.16) respec-
tively. ConClusions: The ranges of disutility in quality of life among patients 
suffering from psoriasis vulgaris identified in this review are within the same range 
as for patients suffering from cancer or cardiovascular diseases.
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objeCtives: To evaluate reliability, validity, and responsiveness of the Psoriasis 
Symptom Diary (PsD) using data from patients with moderate-to-severe chronic 
plaque-type psoriasis. Methods: Analyses were completed using pooled data from 
the screening (1-4 weeks) and induction (12 weeks) periods of two randomized, 
double-blind, double-dummy, placebo-controlled, multicenter phase 3 trials (N = 
820; CAIN457A2302 and CAIN457A2303) designed to assess the safety and efficacy 
of secukinumab. Patients aged 18+ years were randomized 1:1:1 in CAIN457A2302 
to subcutaneous treatment groups (secukinumab 150 mg, secukinumab 300 mg, 
and placebo); and 1:1:1:1 in CAIN457A2303 including an etanercept 50 mg (twice 
per week) group. The 16-item PsD (24-hour recall period; 0 to 10 numerical rat-
ing scale) was electronically administered each evening. Intraclass correlations 
were calculated to estimate test-retest reliability. Construct validity hypotheses 
were evaluated based on correlations with the Psoriasis Area and Severity Index 
(PASI), Investigator’s Global Assessment (IGA), Patient Global Impression of Change 
(PGIC), the Dermatology Life Quality Index (DLQI), and the EuroQol 5-Dimension 
Health Status Questionnaire (EQ-5D). Mean differences between known groups and 
responsiveness effect sizes were computed. Phase 2 derived anchor-based PGIC 
thresholds and cumulative distribution function (CDF) plots were used to describe 
meaningful change. Results: The PsD items yielded high intraclass coefficients (> 
0.90). Correlations were in the anticipated direction and by week 12 were moderate 
to strong (0.41 to 0.73) in magnitude, demonstrating construct validity. Item-level 
